Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- Correlations Between Ofatumumab Exposure and Treatment Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Ofatumumab, Fludarabine, and Cyclophosphamide Chemoimmunotherapy
- Gene Mutations and Treatment Outcome in CLL Patients Treated
- HEALTH RELATED QUALITY OF LIFE AND PATIENT REPORTED OUTCOMES IN PATIENTS RECEIVING OFATUMUMAB MAINTENANCE VERSUS OBSERVATION IN THE PROLONG TRIAL
- NOTCH1 Mutation and Treatment Outcome In CLL Patients Treated With Chlorambucil (Chl) Or Ofatumumab-Chl (O-Chl): Results From The Phase III Study Complement 1 (OMB110911)
- Ofatumumab (OFA) in Combination with CHOP for Previously Untreated Follicular Lymphoma: Follow-up Results
- Ofatumumab (OFA) Maintenance Prolongs PFS in Relapsed CLL: Prolong Study Interim Analysis Results
- Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911)
- Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II T
- Ofatumumab retreatment and maintenance in patients with fludarabine-refractory CLL.
- SF3B1 MUTATIONS AND OUTCOME IN CLL PATIENTS TREATED WITH CHLORAMBUCIL (CHL) OR OFATUMUMAB-CHL (O+CHL): RESULTS FROM THE PHASE III STUDY COMPLEMENT 1 (OMB110911)
- TELOMERE LENGTH AND POT1 MUTATIONS IN CLL: INCIDENCE, ASSOCIATIONS AND CLINICAL IMPACT IN THE COMPLEMENT 1 TRIAL
